This approach represents a shift from general oxidative stress modulation to targeted Nrf2 pathway reactivation through precise molecular interference, providing a promising pharmacological scaffold for ALS drug development. The gene discussed is NFE2L2; the disease is amyotrophic lateral sclerosis.